Klotho Neurosciences Inc. Enters Strategic Partnership with AAVnerGene Inc. to Advance Gene Therapy Innovations

Reuters
07/22
Klotho Neurosciences Inc. Enters Strategic Partnership with AAVnerGene Inc. to Advance Gene Therapy Innovations

Klotho Neurosciences, Inc. (NASDAQ: KLTO) has announced a strategic partnership with AAVnerGene Inc., a biotech company based in Rockville, MD, known for its advanced AAV manufacturing and tissue-targeted delivery technologies. This collaboration aims to address challenges in AAV gene therapy, including high drug costs and dose-related toxicity, by leveraging AAVnerGene's proprietary platforms. The partnership will utilize the AAVone system to reduce manufacturing costs and the ATHENA platform for efficient tissue-targeted delivery. Klotho Neurosciences plans to apply these technologies to accelerate the development of its gene therapy candidates, such as KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS, and KLTO-303 for aging-related conditions. The collaboration is expected to result in more affordable and innovative treatments for both rare and common neurological diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klotho Neuroscience Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA34799) on July 22, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10